NasdaqGS - Delayed Quote USD
REGENXBIO Inc. (RGNX)
At close: October 18 at 4:00 PM EDT
Pre-Market: 7:28 AM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
89,044.00
90,242.00
112,724.00
470,347.00
154,567.00
Cost of Revenue
38,488.00
37,213.00
54,545.00
51,833.00
35,714.00
Gross Profit
50,556.00
53,029.00
58,179.00
418,514.00
118,853.00
Operating Expense
297,218.00
321,157.00
321,055.00
258,534.00
238,086.00
Operating Income
-246,662.00
-268,128.00
-262,876.00
159,980.00
-119,233.00
Net Non Operating Interest Income Expense
-5,428.00
-6,837.00
-22,912.00
-25,558.00
3,500.00
Other Income Expense
10,862.00
11,319.00
5,383.00
6,825.00
9,723.00
Pretax Income
-241,228.00
-263,646.00
-280,405.00
141,247.00
-106,010.00
Tax Provision
--
-152.00
-84.00
13,407.00
5,240.00
Net Income Common Stockholders
-241,076.00
-263,494.00
-280,321.00
127,840.00
-111,250.00
Diluted NI Available to Com Stockholders
-241,076.00
-263,494.00
-280,321.00
127,840.00
-111,250.00
Basic EPS
-5.24
-6.02
-6.50
3.01
-2.98
Diluted EPS
-5.24
-6.02
-6.50
2.91
-2.98
Basic Average Shares
46,072.00
43,734.00
43,152.00
42,438.00
37,281.00
Diluted Average Shares
46,072.00
43,734.00
43,152.00
43,913.00
37,281.00
Total Operating Income as Reported
-248,763.00
-268,128.00
-262,876.00
159,980.00
-119,233.00
Total Expenses
335,706.00
358,370.00
375,600.00
310,367.00
273,800.00
Net Income from Continuing & Discontinued Operation
-241,076.00
-263,494.00
-280,321.00
127,840.00
-111,250.00
Normalized Income
-251,938.00
-274,806.47
-285,702.39
121,662.82
-118,347.79
Interest Income
-19.00
25.00
342.00
719.00
4,271.00
Interest Expense
5,409.00
6,862.00
23,254.00
26,277.00
771.00
Net Interest Income
-5,428.00
-6,837.00
-22,912.00
-25,558.00
3,500.00
EBIT
-235,819.00
-256,784.00
-257,151.00
167,524.00
-105,239.00
EBITDA
-218,881.00
-239,464.00
-244,242.00
177,088.00
-96,832.00
Reconciled Cost of Revenue
38,488.00
37,213.00
54,545.00
51,833.00
35,714.00
Reconciled Depreciation
16,938.00
17,320.00
12,909.00
9,564.00
8,407.00
Net Income from Continuing Operation Net Minority Interest
-241,076.00
-263,494.00
-280,321.00
127,840.00
-111,250.00
Total Unusual Items Excluding Goodwill
10,862.00
11,319.00
5,383.00
6,825.00
9,723.00
Total Unusual Items
10,862.00
11,319.00
5,383.00
6,825.00
9,723.00
Normalized EBITDA
-229,743.00
-250,783.00
-249,625.00
170,263.00
-106,555.00
Tax Rate for Calcs
--
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
6.53
1.61
647.82
2,625.21
12/31/2020 - 9/17/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PRTA Prothena Corporation plc
17.11
+0.29%
APLS Apellis Pharmaceuticals, Inc.
28.00
+0.29%
QURE uniQure N.V.
6.42
+2.23%
VYGR Voyager Therapeutics, Inc.
8.07
+0.75%
MGTX MeiraGTx Holdings plc
6.14
+3.37%
CLSD Clearside Biomedical, Inc.
1.1500
0.00%
RCKT Rocket Pharmaceuticals, Inc.
18.82
+2.12%
VRDN Viridian Therapeutics, Inc.
24.98
+2.97%
ADVM Adverum Biotechnologies, Inc.
8.48
+4.95%
STOK Stoke Therapeutics, Inc.
13.00
-2.03%